Form 4: Glaukos Director Aimee Weisner Reports RSU Grant

Glaukos Corporation Director Aimee S. Weisner reported the acquisition of 623 restricted stock units as part of her compensation.

Summary

• Aimee S. Weisner, a Director of Glaukos Corporation (GKOS), reported changes in her beneficial ownership.
• On January 2, 2026, Ms. Weisner was granted 623 restricted stock units (RSUs) as part of the Issuer's Director Compensation Policy.
• These RSUs will vest in full on the one-year anniversary of the grant date (January 2, 2027) and are payable in an equivalent number of shares of Glaukos common stock.
• Following this transaction, Ms. Weisner directly beneficially owns 19,786 shares of common stock, which includes 2,731 unvested RSUs and vested but deferred RSUs.
• Additionally, Ms. Weisner indirectly beneficially owns 28,525 shares through the Saeman-Weisner Family Trust and 2,000 shares through the Weisner Saeman Family Irrevocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event for a director, which is a standard practice and indicates ongoing commitment. There are no negative implications, but also no significant new positive developments for the company's operations or financial performance.

Positives

• The grant of restricted stock units to Director Aimee S. Weisner aligns her interests with those of shareholders, as the units vest over time and are tied to the company's equity performance.
• This is a routine compensation event for a director, indicating standard corporate governance practices for executive and director remuneration.

Negatives

• No negative information was disclosed in this Form 4 filing, which primarily reports changes in beneficial ownership for an insider.

Risks

• No specific risks were mentioned in this Form 4 filing, as it is a disclosure of an insider transaction rather than a comprehensive risk assessment document.

Future Outlook

The 623 restricted stock units granted to Director Weisner are scheduled to vest in full on January 2, 2027, which is one year from the grant date. These units will be payable in an equivalent number of shares of Glaukos common stock upon vesting.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across various industries, including the medical technology sector where Glaukos operates. Such grants are standard mechanisms for aligning director incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a widely adopted practice in the U.S. public company landscape, consistent with corporate governance standards for attracting and retaining qualified board members.
• The vesting schedule of one year for these RSUs is a common structure for director equity awards, similar to practices observed at comparable medical device companies like Alcon (ALC) or Bausch + Lomb (BLCO), which often use equity to incentivize long-term commitment.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders by tying compensation to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this director compensation filing.

Next Steps

• The 623 restricted stock units granted to Aimee S. Weisner are expected to vest on January 2, 2027, at which point they will be converted into shares of Glaukos common stock.

Key Dates

Keywords

Glaukos Corporation, GKOS, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Beneficial Ownership, Equity Grant